Does a Multi-Ingredient Creatine and MCT Supplement Prevent Muscle Loss in Sarcopenia?

Sarcopenia¹, the progressive loss of muscle mass and strength associated with aging, affects over 20% of older adults in Taiwan, where this trial was conducted, and contributes to frailty and functional decline. While resistance training remains the gold standard for combating sarcopenia, researchers are actively exploring nutritional interventions for those who cannot easily engage in structured exercise. A recent randomized controlled trial investigated whether a multi-ingredient supplement containing creatine, leucine, medium-chain triglycerides (MCTs), and whey protein could mitigate these age-related declines.

Key Takeaways

• Targeted Formulation: The study tested a multi-ingredient supplement combining whey protein, branched-chain amino acids, MCTs, creatine, resveratrol, and vitamin D3 against an isocaloric placebo.
• Statistically Significant but Clinically Trivial Muscle Gains: While the supplement group gained muscle mass compared to the placebo group, the absolute increase fell below the widely recognized threshold for a minimal clinically important difference.
• Strength Preservation: Handgrip strength did not outright improve in the supplemented group. However, the placebo group experienced a 7.0% decline in strength over the eight weeks, a drop that the supplement successfully prevented.

The Study Design

Researchers conducted an eight-week randomized, double-blind, placebo-controlled trial at National Taiwan University Hospital, involving 73 older adults (average age 77.3 ± 7.7 years) who met the Asian Working Group for Sarcopenia (AWGS) 2019 diagnostic criteria. Participants were randomly assigned to receive either the multi-ingredient supplement (n=34) or an isocaloric placebo (n=39) daily, without a structured exercise program. The trial was registered in advance on ClinicalTrials.gov (NCT06376266).

The primary outcomes measured were changes in appendicular skeletal muscle mass (ASM) assessed via dual-energy X-ray absorptiometry (DXA²) and handgrip strength. As an exploratory endpoint, the team also performed targeted plasma amino acid metabolomics to observe shifts in amino acid utilization.

The Findings

After eight weeks, the group receiving the multi-ingredient supplement showed a statistically significant increase in appendicular skeletal muscle mass (+0.42 kg, or +3.2%) compared to the placebo group, which saw no change.

Despite this gain in physical mass, handgrip strength did not significantly differ between the two groups (p=0.32) — the primary strength outcome was null. Within-group analysis offers a more encouraging reading: the placebo group declined significantly by 7.0% (p<0.001), while the supplemented group showed no significant change (p=0.537). It is worth being precise about what that means. "No significant decline" is not the same as demonstrated preservation, and a within-group contrast is weaker evidence than the between-group comparison that found nothing.

Exploratory metabolomic profiling observed shifts in plasma amino acids — reductions in taurine and 1-methylhistidine alongside an increase in kynurenine — but with no clear separation on PCA/PLS-DA, the authors treat these as hypothesis-generating rather than confirmatory of altered proteolysis. Positively, no adverse metabolic or renal events were reported.

Analyzing the Study: Strengths & Limitations

Strengths and Reputability

The study utilized a rigorous double-blind, placebo-controlled design and was registered in advance on ClinicalTrials.gov (NCT06376266) — pre-registration makes it far harder to quietly reframe a null primary outcome after the fact, which matters here given that the primary strength outcome was null. It relied on objective, gold-standard measurements for body composition (DXA), and recruited an at-risk demographic defined by an established clinical standard (AWGS 2019) rather than by self-report.

Limitations

The study suffers from several crucial limitations that impact its broader applicability. First, the modest sample size (n=73) lacks an a priori power calculation, which limits the robustness of the functional outcome data. Second, because the intervention was a multi-ingredient matrix, it is impossible to isolate the specific effects or contribution of the creatine versus the whey, MCTs, or leucine. Third, the cohort was recruited at a single hospital in Taiwan and screened against AWGS criteria, which are calibrated to Asian populations; the findings may not transfer cleanly to other populations or care settings. Finally, and most importantly, the clinical significance of the findings is trivial: the authors explicitly note in the abstract that the observed increase in muscle mass fell below the minimal clinically important difference (MCID³).

Conflicts of Interest

PubMed carries no conflict-of-interest statement for this record. Readers and researchers should consult the full text of the publication to verify if any industry ties or funding sources were disclosed by the authors.

References

1. Effects of a Multi-Ingredient MCT-Leucine-Creatine-Based Supplement (TLN-01) on Muscle Mass, Strength, and Plasma Amino Acid Profiles in Older Adults with Sarcopenia: A Randomized Controlled Trial. Life (Basel, Switzerland). DOI: 10.3390/life16081334

References

1. Chan DC, Shiao MS, Huang WJ, Huang CF. Effects of a Multi-Ingredient MCT-Leucine-Creatine-Based Supplement (TLN-01) on Muscle Mass, Strength, and Plasma Amino Acid Profiles in Older Adults with Sarcopenia: A Randomized Controlled Trial. Life (Basel). 2026;16(8):1334. doi:10.3390/life16081334

Glossary

1. Sarcopenia: A progressive, age-related syndrome characterized by the generalized loss of skeletal muscle mass and strength, increasing the risk of adverse outcomes like physical disability and poor quality of life. ↩

2. DXA (Dual-energy X-ray Absorptiometry): A highly precise imaging technique used to measure bone mineral density and body composition, including fat and lean muscle mass. ↩

3. Minimal Clinically Important Difference (MCID): The smallest change in a treatment outcome that an individual patient or clinician would identify as important, distinguishing a statistically significant finding from a practically meaningful one. ↩